

Name: György M. Keserű

Date of Birth: 31. 08. 1967

<http://lnkd.in/bSJZhD8>

Short biosketch

György M. Keserű obtained his Ph.D. at Budapest, Hungary and joined Sanofi-Aventis CHINOIN heading a chemistry research lab. He moved to Gedeon Richter in 1999 as the Head of Computer-aided Drug Discovery. He earned D.Sc. from the Hungarian Academy of Science in 2003 and he was invited for a research professorship at the Budapest University of Technology and Economics. Since 2007 he was appointed as the Head of Discovery Chemistry at Gedeon Richter. He served as a director general of the Research Center for Natural Sciences (RCNS) at the Hungarian Academy of Sciences. He contributed to the discovery of the antipsychotic Vraylar® (RGH-188, cariprazine) that has been approved by the US FDA in 2015. From 2015 he is heading the Medicinal Chemistry Research Group at RCNS. His research interests include medicinal chemistry, drug design, and in silico ADME. He has published over 150 papers and more than 10 books and book chapters.

Academics:

2015-	Full Professor, Budapest University of Technology and Economics
2003-	Research Professor, Budapest University of Technology and Economics
2003	Doctor habilitate of Budapest University of Technology and Economics
2003	Doctor of the Hungarian Academy of Sciences (D.Sc)
1999-2002	Bolyai Postdoctoral Research Fellow
1994-1996	Magyary Postdoctoral Research Fellow
1994	C.Sc degree from Hungarian Academy of Sciences
1991-1994	Technical University of Budapest, PhD degree
1991	Technical University of Karlsruhe, Germany, Department of Biochemistry, post. grad. study
1986-1991	Technical University of Budapest, Department of Organic Chemistry, M.Sc. degree

Positions:

2015.07. –	Research Centre for Natural Sciences, Hungarian Academy of Sciences, scientific advisor, head of research group
2013.01. – 2015.12.	Research Centre for Natural Sciences, Hungarian Academy of Sciences, Director General
2006. 07.- 2012.12.	Gedeon Richter Plc, Manager, Discovery Chemistry
1999. 01. - 2006. 06.	Gedeon Richter Plc., Unit Head
1996.04. – 1998.12.	Sanofi-Aventis CHINOIN, Lab. Head
1999-	Adjunct Professor at the Department of General and Analytical Chemistry, TUB

Teaching experience:

1993-2003	Molecular modeling, Budapest University of Technology and Economics
2003-	Drug Design, Budapest University of Technology and Economics
2009-2013	Innovation management in pharma research, Budapest University of Technology and Economics
2009-	Drug Design, Eötvös University

Memberships:

American Chemical Society, 1996-
Hungarian Chemical Society, 1996-
Hungarian Biochemical Society, 2004-
American Chemical Society, Hungarian Chapter, secretary, 2005-2009
Hungarian Biochemical Society, section head, 2006-
Molecular Diversity (Springer) editorial board member, 2006-
Drug News and Perspectives (Thomson Reuters) editorial board member, 2009-
Drugs of Future (Thomson Reuters) editorial board member, 2009-
Letters in Drug Design & Discovery (Bentham Science) editorial board member, 2011-
Scientifica (Hindawi), editorial board member, 2012-
Drug Discovery Today: Technologies (Elsevier), editorial board member, 2013-
Archives der Pharmacie (Wiley), editorial board member, 2015-

Awards:

Zoltán Földi Award in Organic Chemistry, 1995
Young Investigators Award, 1996, Hungarian Chemical Society
Academy Award, 1998, Hungarian Academy of Sciences
Kisfaludy Award, 1999, Kisfaludy Foundation
George Olah Award of the Hungarian Academy of Sciences, 2001
Kajtár Award, 2002, Kajtár Foundation
Academy Publication Award of the Hungarian Academy of Sciences, 2006
Academy Publication Award of the Hungarian Academy of Sciences, 2012
Overton and Meyer Award, European Federation of Medicinal Chemistry, 2014

Major grants:

Hungarian Science Foundation T 015495 Synthesis and chiral recognition of 1,3-dideuteroallenes (1995-1996)

Hungarian Science Foundation F 019261 Optimization of diastereomeric separations (1996-1999)

Hungarian Science Foundation F 030044 Application of theoretical and preparative models for enzymatic reactions (1999-2002)

Hungarian Science Foundation T 042933 Conformational and electronic changes in proteins (2003-2007)

National Brain Research Program KTIA NAP_13 Fragment based approaches for the validation of new CNS targets (2013-2017)

Hungarian Science Foundation K 116904 Discovery of Janus kinase inhibitors (2015-2019)

European Commission H2020-MSCA-ITN-2015 Proposal Number: 675899 FRAGNET, Marie Curie FRAGments training NETwork (2016-2020)

Publications (1992-2013):

185 papers in international journals

3308/2782 independent citations, ~300+ citations/year from 2010 (Scopus)

Total impact (IF): 521

Hirsch index: 30

13 book chapters

5 books (including *Molecular Mechanics and Conformational Analysis in Drug Design* Blackwell Science, Oxford, UK, 1999 and *Thermodynamics and Kinetics of Drug Binding*, Wiley, 2015)

41 international patent applications

Regular reviewer for:

Bioorganic and Medicinal Chemistry

Bioorganic and Medicinal Chemistry Letters

ChemMedChem

ChemBioChem

European Journal of Medicinal Chemistry

Journal of Medicinal Chemistry

Journal of Computer Aided Molecular Design

Journal of Chemical Information and Modeling

Professional experience:

- 20+ y management experience (lab. head, unit head, section head, managing director)
- 17+ y experience in pharma research
- 14+ y experience in academic research
- Collaborative pharma research experience with US and Japanese companies
- Collaborative academic research experience with European partners
- demonstrated expertise in medicinal chemistry and drug design

Drug discovery track record:

direct involvement pushing 10 compounds (41 patent applications) into development (2000-2012)

- two compounds in schizophrenia including Cariprazine (head of CADD)
- two compounds in neuropathic pain (head of Lead Discovery)
- two compound in anxiety (head of Discovery Chemistry)
- two compound in inflammatory pain (head of Discovery Chemistry)
- two compound in Alzheimer's dementia (head of Discovery Chemistry)

Cariprazine (RGH-188) has been approved on the trade name Vraylar® for schizophrenia and bipolar disorder by the US FDA in 2015.